Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.
about
Idiopathic Inflammatory Myopathies: Clinical Approach and ManagementEmerging therapeutic options for sporadic inclusion body myositisScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesDevelopments in the classification and treatment of the juvenile idiopathic inflammatory myopathiesImmunotherapies for Immune-Mediated Myopathies: A Current PerspectiveCutaneous dermatomyositis in the era of biologicals.An expanding role for interleukin-1 blockade from gout to cancer.Drugs in induction and treatment of idiopathic inflammatory myopathiesCytokine Therapies in Neurological Disease.Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets.Role of MRI in diagnosis and management of idiopathic inflammatory myopathies.Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.The EuroMyositis registry: an international collaborative tool to facilitate myositis research.Current pharmacological treatment of idiopathic inflammatory myopathies.2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects
P2860
Q26744705-549173B4-CF4E-4045-9CBB-33956D1AADCCQ26786571-C9A91F7F-3031-4D19-88E8-C83D2608135CQ26798209-BFE03D3A-D9DD-4756-BED0-1FE77E1ACFF3Q26863125-8775154F-60C5-49D9-BD42-CEC1D2C92989Q30699742-868CCBF6-7469-46DC-A14E-3290DB0F506CQ34501531-91FFF7DC-F6E5-495C-A2F6-E72F7AA633F6Q35219001-72C10D0E-1032-46C4-9388-1B66949B8F5AQ35281940-187A5CA0-70D2-4DE0-868E-81637199CE01Q37136498-BF28377A-B201-4439-9712-6A358A6D64D5Q38244567-EE5F0F80-38E9-4B09-A104-7B8278273D29Q38589301-026054B3-DF79-485B-896C-13627D983F36Q38589395-65A7A401-CEAC-4B43-9CA8-6FACF8579101Q38597575-470D9ACA-64EB-41EC-8245-87C8ED4CF370Q38601741-4DEEF58F-ADD3-48E7-8902-5740E7E63BE9Q38680762-9E17E10A-C9EA-4B47-921B-699745BAA5C0Q58490673-63A5CB1D-9387-4B85-9CDE-365F2E73ED96
P2860
Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@en
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@nl
type
label
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@en
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@nl
prefLabel
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@en
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@nl
P2093
P2860
P1476
Anakinra treatment in patients ...... tudy with 12 months follow-up.
@en
P2093
Christina Dorph
Helene Alexanderson
Inger Nennesmo
Jennifer Pieper
Maryam Dastmalchi
Petra Amoudruz
Sevim Barbasso Helmers
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202857
P407
P577
2013-04-26T00:00:00Z